Stock Analiz

Eloxx Pharmaceuticals, Inc. ELOX

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$13.15Market cap $53M
Open the interactive analysis →

Eloxx Pharmaceuticals, Inc. (ELOX) is a healthcare company listed in the US with a market value of about $53M.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -724%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 91% below the current price.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals is listed in the US and classified in biotechnology: biological products (no diagnostic substances). It was profitable in 0 of the last 10 years in our data. Its share count rose by 470% over three years (dilution for shareholders).

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.1
EV/EBITDA—
PEG—
Dividend yield—
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−91%

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-49.4%
ROIC (5-yr avg.)-723.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$0$6M$0———————
Net income-$6M-$3M-$17M-$36M-$67M-$35M-$51M-$47M-$21M-$10M
Free cash flow———-$32M-$35M—-$39M-$32M-$16M-$9M
EPS (diluted)$-0.49$-0.84$-6.63$-16.65$-38.15$-0.86$-1.34$-1.45$-4.75$-2.60
Net margin—-49.4%————————
ROIC———-1263.5%-184.2%-150.2%-97.3%-87.6%-75.4%-1274.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Eloxx Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 91% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Eloxx Pharmaceuticals pay a dividend?

Not currently.

Is Eloxx Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Eloxx Pharmaceuticals scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.